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a b s t r a c t
Neuroinflammation plays a critical role in the pathogenesis of traumatic brain injury (TBI). TBI induces
rapid activation of astrocytes and microglia, infiltration of peripheral leukocytes, and secretion of inflam-
matory cytokines. In the context of modest or severe TBI, such inflammation contributes to tissue
destruction and permanent brain damage. However, it is clear that the inflammatory response is also nec-
essary to promote post-injury healing. To date, anti-inflammatory therapies, including the broad class of
non-steroidal anti-inflammatory drugs (NSAIDs), have met with little success in treatment of TBI, perhaps
because these drugs have inhibited both the tissue-damaging and repair-promoting aspects of the
inflammatory response, or because inhibition of inflammation alone is insufficient to yield therapeutic
benefit. Salsalate is an unacetylated salicylate with long history of use in limiting inflammation. This drug
is known to block activation of NF-jB, and recent data suggest that salsalate has a number of additional
biological activities, which may also contribute to its efficacy in treatment of human disease. Here, we
show that salsalate potently blocks pro-inflammatory gene expression and nitrite secretion by microglia
in vitro. Using the controlled cortical impact (CCI) model in mice, we find that salsalate has a broad anti-
inflammatory effect on in vivo TBI-induced gene expression, when administered post-injury.
Interestingly, salsalate also elevates expression of genes associated with neuroprotection and neurogen-
esis, including the neuropeptides, oxytocin and thyrotropin releasing hormone. Histological analysis
reveals salsalate-dependent decreases in numbers and activation-associated morphological changes in
microglia/macrophages, proximal to the injury site. Flow cytometry data show that salsalate changes
the kinetics of CCI-induced accumulation of various populations of CD11b-positive myeloid cells in the
injured brain. Behavioral assays demonstrate that salsalate treatment promotes significant recovery of
function following CCI. These pre-clinical data suggest that salsalate may show promise as a TBI therapy
with a multifactorial mechanism of action to enhance functional recovery.
Published by Elsevier Inc.
1. Introduction
TBI is a major cause of morbidity and mortality throughout
the world, with resultant healthcare costs representing a huge
economic burden for developed countries (Fu et al., 2016).
However, despite decades of basic research and clinical studies,
there is not yet an accepted therapy for TBI, and treatment remains
limited to supportive care. There thus remains an urgent need to
identify novel therapeutics for this devastating class of injuries.
Neuroinflammation plays a central role in the pathophysiology
of TBI. Tissue damage and destruction following TBI involves both
the primary injury, in which brain tissue is directly damaged by the
physical insult, and a secondary injury, in which direct tissue dam-
age is further amplified by a variety of consequent processes,
including tissue necrosis, ischemia, and activation of the inflamma-
tory cascade (Hellewell et al., 2015; Kumar and Loane, 2012).
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Among the cellular components of the neuroinflammatory
response post-TBI, microglia and astrocytes play a prominent role
in the induction and regulation of inflammation. Microglia are
CNS-resident myeloid lineage cells which serve as immune sen-
tinels, as well as playing many other roles in CNS physiology
(Marin and Kipnis, 2016; Tay et al., 2016). Upon activation by
endogenous ‘‘danger” signals produced by damaged or necrotic
cells, microglia release numerous pro-inflammatory mediators
including cytokines, chemokines, reactive oxygen species (ROS)
and nitric oxide (NO) (DeLegge and Smoke, 2008; Kettenmann
et al., 2011; Qin et al., 2007). Astrocytes also undergo phenotypic
changes in response to TBI, increasing in size, upregulating produc-
tion of glial fibrillary acidic protein (GFAP) and vimentin, and
releasing inflammatory mediators (Gorina et al., 2011; Paintlia
et al., 2013; Sofroniew and Vinters, 2010; Zamanian et al., 2012).
Surprisingly, data suggest that the post-TBI inflammatory
response can persist for decades in humans (Smith et al., 2013).
Evidence is accumulating that persistent neuroinflammation after
TBI is a major driver of neurodegeneration (Faden and Loane,
2015). Given the extended time scale of inflammation-induced tis-
sue injury, the reduction of neuroinflammation is a particularly
important intervention strategy to limit TBI-driven tissue destruc-
tion. Indeed, considerable effort is being directed towards the
development of therapeutics to ameliorate neuroinflammation
(Hellewell et al., 2015). To date, however, trials of various candi-
date anti-inflammatory therapies have not yielded compelling evi-
dence of clinical benefit in TBI.
Many now argue that TBI is too biologically complex to treat
successfully by targeting a single aspect of the injury-induced
pathology (Loane et al., 2015; Margulies et al., 2009; Stoica et al.,
2009; Vink and Nimmo, 2009). In this respect, it would be desirable
to identify candidate TBI therapeutics that both reduce inflamma-
tion and possess other biological activities that mitigate damage
and promote a successful healing response.
The transcription factor NF-jB is a primary driver of the host
immune response, including the inflammatory cascade
(Vallabhapurapu and Karin, 2009). Our previous work has demon-
strated a prominent NF-jB transcriptional signature, including
many inflammation-associated gene products, following both
minor and severe brain injury (Lagraoui et al., 2012). Thus, a logical
approach to limit TBI-dependent inflammation would be to inhibit
NF-jB activation, post-injury. We therefore sought to identify FDA-
approved drugs that are known to inhibit NF-jB activation and to
cross the blood-brain barrier (BBB). One such drug meeting these
criteria is salsalate, a non-steroidal anti-inflammatory drug
(NSAID), which, like aspirin, is a salicylate. Salicylate-based drugs
have a long history of clinical application (Hedner and Everts,
1998). A key distinction between salsalate and aspirin is that sal-
salate is a non-acetylated salicylate. Acetylated salicylates, includ-
ing aspirin, irreversibly inactivate cyclooxygenase (COX) enzymes,
which accounts for their potent inhibition of the clotting cascade.
Lacking this acetyl group, salsalate is a weak and reversible COX
inhibitor, which does not have significant anti-coagulant activity
(Marnett, 2009). However, like aspirin, salicylate (the metabolized
product of salsalate) potently suppresses NF-jB activation through
inhibition of the enzymes IjB kinase (IKK)-a and IKK-b (Kopp and
Ghosh, 1994; Pierce et al., 1996; Yin et al., 1998). Moreover, recent
studies demonstrate that salsalate (and/or salicylate) has several
other biological activities independent of effects on the NF-jB
pathway, with at least one activity that appears to protect against
neurodegeneration (Hawley et al., 2012; Min et al., 2015;
Shirakawa et al., 2016). Thus, salsalate may have the desired mul-
timodal mechanism of action to be considered a candidate TBI
therapy.
In this study, we investigated the therapeutic efficacy of sal-
salate treatment for TBI, using the well-established CCI model in
mice. We first demonstrated that salsalate potently inhibits
inflammatory gene expression and functional responses in a
microglia cell line, confirming that salsalate is capable of inhibiting
a cell population which plays a central role in the CNS inflamma-
tory response (Karve et al., 2016). Then, employing the CCI model,
we used an unbiased transcriptomics approach to demonstrate
that the primary effect of salsalate on TBI-induced transcription
is suppression of a gene set that is highly enriched in
NF-jB-regulated mediators of inflammation. However, salsalate
also modestly induced a cohort of genes. This induced subset is
nearly devoid of pro-inflammatory genes, and highly enriched in
known mediators of neuroprotection and neurogenesis. Of particu-
lar interest in the induced subset were the transcripts encoding the
neuropeptides oxytocin and thyrotropin releasing hormone, both
of which are known to mediate protective effects in TBI. We
furthermore performed histological analysis of glial expansion,
finding a significant reduction in the population of activated
microglia/macrophages at the injury site, with a possible reduction
in activated astrocytes, providing further evidence of salsalate-
mediated suppression of the inflammatory response. In addition,
flow cytometry data demonstrated that salsalate treatment altered
kinetics of accumulation of distinct populations of infiltrating
blood leukocytes in the injured brains. Assays of motor function
revealed that salsalate treatment promotes significant recovery
during the week post-injury. Together, these data suggest that sal-
salate promotes recovery from traumatic brain injury via both
inhibition of inflammation and induction of a gene expression pro-
gram associated with neuroprotection and neurogenesis. The
potential multifactorial mode of protection suggests that salsalate
may be particularly promising as a therapeutic candidate for the
treatment of human TBI.
2. Materials and methods
2.1. BV2 cell culture and gene expression assays
The murine microglia line, BV-2 (Blasi et al., 1990), was cultured
in DMEM supplemented with 10% FBS and 1% pen/strep at 37 C in
a humidified incubator with 5% CO2. Cells were seeded in 6-well
plates at a density of 5  105 cells/well. After overnight incubation,
the culture medium was changed, and cells were pretreated with
salsalate (0.5, 1, 2, and 3 mM) or vehicle (1xPBS) for 1 h, followed
by stimulation with 0.5 lg/ml LPS. After 24 h of LPS stimulation,
supernatant was collected and stored at 20 C and cells were pro-
cessed for RNA isolation. RT-PCR was performed as described
below.
2.2. Nitrite measurement
BV2 microglia cells were cultured overnight in 6 well plates in a
density of 5  105 cells/well and pretreated with salsalate (0.5, 1, 2,
and 3 mM) or vehicle for 1 h, then stimulated with 0.5 lg/ml LPS or
vehicle (1  PBS) for 24 h. After incubation, the culture medium
was collected and stored at 20 C until performance of the assay.
Release of nitric oxide was quantified by measuring the stable
metabolite, nitrite, using a Nitrate/Nitrite assay kit (Sigma, St.
Louis, MO), according to the manufacturer’s instructions.
2.3. Animals and surgical procedures
Ten- to twelve-week old C57BL/6 male mice were subjected to
TBI using an Impact OneTM Stereotaxic Impactor (myNeuroLab, St.
Louis, MO, USA), as we have previously described (Lagraoui et al.,
2012). Briefly, mice were anesthetized with 2% isoflurane in 98%
oxygen, followed by positioning in a stereotaxic frame. Craniotomy
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was performed over the left hemisphere using a hand-held 5 mm
trephine over the motor cortex (1.8 mm medial-lateral, 2 mm
from Bregma). Mice were then subjected to CCI using a 3 mm
flat-tip with a velocity of 5 m/s at a depth of 2.0 mm for 200 ms.
After trauma, the craniotomy was closed with the previously
removed bone and bone wax, and the incision was closed with
sutures. Naïve mice were anesthetized with 2% isoflurane in 98%
oxygen, monitored until recovery from anesthesia, and transferred
to fresh cages. Animals were not treated (naïve) or i.p. injected
with 50 mg/kg salsalate (Alfa Aesar, MA) or vehicle (DMSO-PBS)
30 min post-CCI and once daily for five consecutive days. The Insti-
tutional Animal Care and Use Committee at Uniformed Services
University (USU) approved all animal procedures.
2.4. Tissue harvesting and RNA extraction
Animals were sacrificed on day +3 post-CCI for transcriptome
profiling and real-time PCR experiments. Mice were perfused with
1  PBS and brains were removed from the skull. A 5 mm diame-
ter punch biopsy encompassing the exact injury site on the left
hemisphere was collected from each CCI animal. The equivalent
region was collected from control (naïve) animals. The depth of
the punch was approximately 5 mm. RNA extraction from both
in vitro cell cultures and biopsy tissue was via the guanidinium
isothiocyanate-phenol extraction method (Chomczynski and
Sacchi, 1987).
2.5. Transcriptome profiling by RNA sequencing
Total RNA was quantified via a fluorescence dye-based method-
ology (RiboGreen) on a Spectramax Gemini XPS plate reader
(Molecular Devices, Mountain View, CA). RNA integrity was
assessed using gel-based electrophoresis on an Experion Auto-
mated Electrophoresis System (Bio-Rad, Hercules, CA). Total RNA
input of 200 ng was used for library preparation using the TruSeq
Stranded mRNA Library Preparation Kit (Illumina, San Diego, CA).
Sequencing libraries were quantified by PCR using KAPA Library
Quantification Kit for NGS (Kapa, Wilmington, MA) and assessed
for size distribution on an Experion Automated Electrophoresis
System. Sequencing libraries were pooled and sequenced on a
NextSeq 500 Desktop Sequencer (Illumina) using a NextSeq 500
High Output Kit v2 with paired-end reads at 75 bp length. Raw
sequencing data was demuxed using bcl2fastq2 Conversion Soft-
ware 2.17 before alignment using TopHat Alignment v1.0 and dif-
ferential expression analysis using Cufflinks Assembly & DE v1.1.0
on BaseSpace Onsite (Illumina).
2.6. Real-time PCR analyses
RNA samples (2 lg) were reverse transcribed to cDNA, using
random hexamers and Superscript II Reverse Transcriptase (Life
Technologies, Carlsbad, CA, USA), in a 1 h reaction at 42 C. Real-
time PCR analysis of cDNA was performed using an RT-PCR master
mix for TaqMan assays (SydLabs, Inc., Malden, MA, USA) and an iQ5
instrument (Bio-Rad, Hercules, CA, USA) in 96-well format with
20 ll reaction volume per well. Primers for TaqMan assays were
designed using Primer Express 3.0 software (Life Technologies,
Carlsbad, CA, USA) or a web based RealTime qPCR Assay design
platform (Integrated DNA Technologies, Coralville, IA). PCR primers
and FAM-ZEN-Iowa Black double-quenched probes were pur-
chased from Integrated DNA Technologies (Coralville, IA, USA). Pri-
mer sequences are listed in Table 1. GAPDH was used as a
normalization control for all probe sets.
The delta Ct (DCt) method was used for PCR array data analysis.
The normalized DCt for each gene of interest (GOI) was calculated
by deducting the Ct of the housekeeping gene (HKG: GAPDH) from
Table 1
Real-time PCR primers.
IL-1b
Sense
GAGCACCTTCTTTTCCTTCATCTT
anti-sense
CACACACCAGCAGGTTATCATCA
Probe
AGAAGAGCCCATCCTCTGTGACTCATGG
Tnf-a
Sense
GGTCCCCAAAGGGATGAGAA
anti-sense
TGAGGGTCTGGGCCATAGAA
Probe
TTCCCAAATGGCCTCCCTCTCATCA
Ccl2
Sense
GGCTCAGCCAGATGCAGTTAA
anti-sense
CCTACTCATTGGGATCATCTTGCT
Probe
CCCCACTCACCTGCTGCTACTCATTCA
Ccl5
Sense
GGGTACCATGAAGATCTCTGC
anti-sense
GCGAGGGAGAGGTAGGCAAAG
Probe
TGAGGATGATGGTGAGGGCAGC
Cxcl10
Sense
TCAGCACCATGAACCCAAG
anti-sense
CTATGGCCCTCATTCTCACTG
Probe
TGCCGTCATTTTCTGCCTCATCCT
MMP13
Sense
TTGATGCCATTACCAGTCTCC
anti-sense
ACATGGTTGGGAAGTTCTGG
Probe
AGCAGGTTGAGGCTGAGCTCTTT
MNDA
Sense
CCAGTCACCAATACTCCACAG
anti-sense
GAGCACCATCACTGTCAGG
Probe
AACCCCAGAACCAGAACATTCCCA
Eomes
Sense
CACCCAGAATCTCCTAACACTG
anti-sense
AGCCTCGGTTGGTATTTGTG
Probe
AAATCTCCTGCCTCATCCAGTGGG
Oxytocin
Sense
TGCTTGGCTTACTGGCTC
anti-sense
GCAGATGCTTGGTCCGAAG
Probe
CCTCGGCCTGCTACATCCAGAAC
Lhx8
Sense
ACAGTTCGCTCAGGACAAC
anti-sense
AAGAATGGTTGGGACTGACG
Probe
AGAAACTGGCAGAAAGGACAGGCT
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the Ct of each GOI: DCt = (CtGOI  CtHKG). The DDCt for each GOI
was calculated by deducting the average DCt of GOI in the naïve
group from the DCt of each GOI in the CCI group: DDCt = DCt
(CCI group)  average DCt (naïve group). The fold-change of each
GOI compared to the naïve group was calculated as: Fold-
change = 2(DDCt).
2.7. Histology
For immunofluorescence microscopy analysis, mice (6 animals
per group) were sacrificed at day +7 following CCI. Brains were per-
fused with cold PBS then with 4% paraformaldehyde. Brains were
dissected from the animal and incubated in 4% paraformaldehyde
for 8–10h, followed by transfer to a solution of 30% sucrose, with
incubation at 4 C for 14 to 16 h. Brains were then frozen in
Tissue-Tek OCT (Sakura Finetek, Torrance, CA, USA) and stored at
80 C. Coronal cryosections (20 lm) were collected and stored
at 80 C until immunostaining. Astrocytes were identified by
staining with an AlexaFluor 555-conjugated GFAP Mouse mono-
clonal antibody (Cell Signaling Technology; Danvers, MA). Micro-
glia were detected via staining with a Rabbit anti-Iba1 polyclonal
antibody (Wako Chemicals USA; Richmond, VA) using an Alexa-
Fluor 488 Goat anti-Rabbit IgG secondary reagent (Thermo Fisher
Scientific; Waltham, MA). Slides were examined using a fluores-
cent microscope (Leica DM5500 B), employing a 40 objective.
GFAP and Iba-1 immunostained brain sections were analyzed
using ImageJ software to quantify the intensity for each image. A
cell counter plugin for ImageJ was used to determine cell number
per unit area.
2.8. Flow cytometry
On days +3 and +7 post-CCI, mice (4 per treatment condition)
were sacrificed and brains were collected and processed for flow
cytometry. Briefly, mice were perfused with 1  PBS and brains
were harvested and digested with collagenase III (Worthington
Biochemical, Lakewood, NJ) and dispase (Roche, via Sigma-
Aldrich, St Louis, MO). Cells were isolated using a 70%, 37%, 30%
Percoll gradient (GE-Healthcare Biosciences, via Sigma-Aldrich, St
Louis, MO) in 1  PBS solution. After isolation, cells were treated
with anti-Fc block and stained with the following antibodies:
V450 anti-CD45.2, PerCP-Cy5.5 anti-CD11b, FITC anti-Ly6G, and
BV605 anti-Ly6C (BD Biosciences, San Jose, CA). After staining, cells
were washed, fixed, and analyzed using an LSR II cytometer (BD
Biosciences, San Jose, CA) and FlowJo 10.2 software (FlowJo, LLC,
Ashland, OR).
2.9. Behavior studies
Rotarod and balance beam tests were performed (9 mice per
group) on days; 1, +1, +3, and +7 relative to surgical procedures,
as we have previously described (Lagraoui et al., 2012). Briefly, for
rotarod testing, mice were acclimated to the apparatus (Ugo Basile,
Collegeville, PA, USA) for 60 s at a fixed speed of 5 rpm. After the
adaptation phase, animals were placed on the rotarod and the
acceleration was increased from 5 to 60 rpm within 180 s. Latency
to fall from the accelerating rotarod and the maximal attained
speed were recorded for each mouse. Three trials were performed
for each animal and the average was recorded. For balance beam
testing, mice were placed on a narrow beam (0.5 cm) and trained
to cross the beam for three consecutive days before the first test.
On the testing day, the mice were placed on the beam and the time
spent to cross and the number of foot-slips occurring during the
beam cross were recorded. Three trials were performed for each
animal and the average was calculated. The beam cross score
was calculated using the formula: (F/C)  T, where F = number of
foot slips, C = length of beam (80 cm) and T = time spent to cross
the beam.
2.10. Statistical analyses
For in vitro experiments (RT-PCR and Nitrite release), one-way
ANOVA with Dunnett’s multiple comparisons test was used to
determine significance. For in vivo experiments (CCI), the Mann-
Whitney U test was used to analyze Real-time PCR results; one-
way analysis of variance (ANOVA) with Tukey’s multiple compar-
isons test was used to analyze GFAP and Iba1 histology results;
two-way ANOVA with Tukey’s multiple comparisons test was used
to analyze flow cytometry data; two-way ANOVA with Tukey’s
multiple comparisons test (within groups) and Sidak’s multiple
comparisons test (between groups) was used for behavior data
statistics. A p value <0.05 was considered statistically significant.
3. Results
3.1. In vitro inhibition of microglia proinflammatory responses by
salsalate treatment
Salsalate has previously been demonstrated to potently inhibit
NF-jB signaling through blocking activation of both IKKa and IKKb
(Kopp and Ghosh, 1994; Pierce et al., 1996; Yin et al., 1998). As the
production of pro-inflammatory cytokines is highly dependent on
intact IKKb activity, we predicted that salsalate treatment would
block stimulus-dependent production of pro-inflammatory media-
tors by sentinel immune cells in the CNS. To provide in vitro data to
directly support this prediction, we pretreated the murine
microglia cell line, BV2, with a range of concentrations of salsalate,
from 0.5 mM to 3 mM. BV2 cells were then stimulated with the
TLR4 agonist, bacterial lipopolysaccharide (LPS), to induce tran-
scription of NF-jB-dependent proinflammatory cytokines. As
shown in Fig. 1A, all four doses of salsalate potently inhibited
LPS-dependent transcription of IL-1b and TNF-a, two key pro-
inflammatory cytokines. We also analyzed the effect of salsalate
pre-treatment on an inflammation-associated microglia functional
response, the secretion of nitrite. As shown in Fig. 1B, we observed
a dose-dependent decrease in LPS-stimulated secretion of nitrite in
BV2 cells which had been pretreated with escalating amounts of
salsalate. Together, these data show that salsalate pretreatment
substantially inhibits NF-jB-dependent inflammatory responses
of microglia in vitro.
3.2. Salsalate treatment reduces expression of proinflammatory genes
and increases expression of genes associated with neuroprotection
and/or neurogenesis
As data suggest that microglia play a key role in initiating and
maintaining the inflammatory response to TBI (Loane and Byrnes,
2010), the data in Fig. 1 suggested that salsalate treatment may
be useful for modulating such responses in vivo. To assess the
in vivo therapeutic efficacy of salsalate as a TBI therapy, we utilized
the mouse CCI model, in which we have previously shown that
injury induces both a strong NF-jB-dependent inflammatory
response and a significant impairment of motor function, which
GAPDH
Sense
TGTGTCCGTCGTGGATCTGA
anti-sense
CCTGCTTCACCACCTTCTTGA
Probe
CCGCCTGGAGAAACCTGCCAAGTATG
M. Lagraoui et al. / Brain, Behavior, and Immunity 61 (2017) 96–109 99
recovers to pre-injury levels by day +7 post-injury (Lagraoui et al.,
2012).
Mouse CCI experiments included three groups: naïve (no CCI, no
treatment), vehicle (CCI, DMSO treatment) and salsalate (CCI, sal-
salate treatment). Administration of salsalate was once per day for
five days, starting 30 min post-injury. In a previous study of
CCI-induced inflammation, we found peak induction of themajority
of inflammatory genes occurred by day +3 post-injury (Lagraoui
et al., 2012). Thus, we chose a five day drug administration time
course to encompass this acute phase of post-CCI inflammation.
For initial salsalate administration, we chose the 30 min post-
injury time point, as we considered this a reasonable model for
administration of therapeutic intervention following acute human
TBI. Although salsalate is administered to human patients via oral
ingestion, oral gavage of salsalate at 30 min post-CCI injury would
require considerable manipulation of animals while in a fragile
post-injury state. We therefore delivered salsalate via intraperi-
toneal injection, which can be performed rapidlywithminimal han-
dling of injured mice. Salsalate is processed to salicylic acid via the
action of a broad class of aryl hydrolases which are expressed in all
tissues,with abundant presence in the blood. Indeed,much process-
ing of ingested salsalate occurs in the blood (Cao et al., 2012;
Harrison et al., 1981). Thus, IP-administered salsalate should be
processed rapidly to salicylic acid.Moreover, systemic release of sal-
icylic acid is likely to be more rapid by injection than via gavage/
ingestion, because transit through the acidic environment of the
stomach (where no processing occurs) is avoided.
For initial assessment of the effects of salsalate treatment on the
response to TBI, we employed an unbiased transcriptomics
approach, using a small cohort of animals (4 per treatment group).
We chose day +3 as our analysis time point, since our previous
analysis of the inflammatory response to CCI demonstrated that
day +3 is the peak of expression for many inflammatory tran-
scripts, with significant elevation of expression for most other
inflammation-associated transcripts that we analyzed (Lagraoui
et al., 2012). As anticipated (Fig. 2A), we observed a high asymme-
try of injury-associated differential gene expression in the
CCI-vehicle group as compared to the naïve experimental group
(1425 genes induced versus 105 genes repressed, at greater than
2-fold ratio in expression), consistent with our previous analysis
by BeadArray RNA expression profiling (Lagraoui et al., 2012). Of
the gene set with increased expression in the CCI-vehicle group,
411 of the 1425 genes are enriched for association with innate
immune responses to cellular stress (p-value = 1.06e64). In com-
parison, the magnitude of differential gene expression in the CCI-
salsalate group as compared to the CCI-vehicle is significantly
reduced, with the majority of genes being repressed (81 genes
induced versus 222 genes repressed). A selection of 12 inflamma-
tory mediators with statistically significant repression is shown
in Fig. 2C. By contrast, of the 81 mRNAs induced by salsalate treat-
ment, only 3 are annotated as being mediators of inflammation
(not significant, p-value = 1e0). Moreover, we also identified a set
of 28 transcripts in the group with statistically significant differen-
tial expression that are well-validated as targets of NF-jB (Pahl,
1999). Importantly, 26 of 28 (93%) were downregulated by sal-
salate treatment (Fig. 2D), and many of these genes overlap with
the set of inflammatory mediators identified in the analysis of
Fig. 2C. Overall, these data are highly consistent with our in vitro
data demonstrating repression of the microglia NF-jB-dependent
pro-inflammatory response (Fig. 1).
Interestingly, we noted that the salsalate-induced transcripts
are enriched in several classes of genes associated with neuropro-
tection and/or neurogenesis, with 14 significantly elevated tran-
scripts shown in Fig. 2E. These included neurogenic transcription
factors (Eomes, Lhx8), dopamine receptors (Drd1a, Drd2), recep-
tors for retinoids (Rarb, Rxrg), and neuropeptides (Oxt, Trh, Avp).
Notably, the salsalate-induced genes segregated into three distinct
patterns of gene induction, with the three neuropeptides repre-
senting a distinct group with a highly uniform pattern of
expression.
We next used real-time PCR analysis of RNA obtained from a
larger cohort of animals (8 per group) to confirm the transcrip-
tomics data of Fig. 2C–E. For each of the pro-inflammatory tran-
scripts tested, we consistently observed a reduction in expression
levels in salsalate-treated animals vs. vehicle-only controls,
although these reductions reached statistical significance for only
Tnf-a and Ccl5 (Fig. 3A). Thus, although CCI-induced pro-
inflammatory gene expression is reduced in vivo by salsalate treat-
ment, the effect is modest in comparison to the magnitude of
in vitro suppression of LPS-induced pro-inflammatory gene expres-
sion in microglia (Fig. 1A).
We also performed real-time PCR analyses to confirm salsalate-
dependent elevations of expression of selected genes identified in
Fig. 2E. These data confirmed that expression of the oxytocin,
Eomes, and Lhx8 genes are elevated by salsalate treatment, with
the increase in oxytocin expression being statistically significant
(Fig. 3B). These data suggest that the effect of salsalate treatment
on TBI is broader than inhibition of inflammation, and that it
may also induce a neuroprotective response.
Fig. 1. Salsalate treatment of the BV2 microglia cell line inhibits LPS-induced
inflammatory responses. (A) TaqMan real-time PCR analysis of salsalate-mediated
repression of LPS-stimulated IL-1b and TNF-a gene expression in BV2 microglia
cells. (B) Quantification of nitrite release by untreated and salsalate-treated BV2
microglia cells, following LPS treatment. ****p < 0.0001 and **p < 0.01, one-way
ANOVA with Dunnett’s multiple comparisons test.
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To provide further evidence that salsalate activity acts beyond
the NF-jB-regulated pro-inflammatory cascade, we performed a
correlation analysis of a subset of genes in the above dataset. As
expected, CCI-induced expression of the NF-jB-regulated pro-
inflammatory gene, TNF-a, was highly correlated with other NF-
jB-regulated mediators of inflammation (Ccl5, IL-1b, Ccl2), but
not with expression of the oxytocin gene (Fig. 3C), which is regu-
lated in a manner independent of NF-jB (Burbach et al., 2001;
Gainer, 2012). Collectively, the data in Figs. 2 and 3 suggest that
salsalate treatment of CCI-injured animals modestly represses the
pro-inflammatory cascade, at least in part through its known activ-
ity as a potent NF-jB inhibitor. However, our data also suggest a
previously unrecognized activity of salsalate: increasing transcrip-
tion of a number of genes associated with neuroprotection and
neurogenesis. Induction of at least one of these genes appears to
be independent of salsalate’s effects on the NF-jB pathway.
3.3. Post-injury administration of salsalate inhibits inflammation-
associated morphological changes in microglia/macrophages
To assess the effect of post-CCI administration of salsalate on
in vivo activation of sentinel cells, we performed immunofluores-
cent microscopy analyses of microglia/macrophages at the site of
injury at day +7, relative to CCI (we employed Iba1 staining, which
does not discriminate between microglia and infiltrating monocytes/
macrophages in CCI-injured animals, and we thus refer to these
cells as microgia/macrophages). As previously reported (Jin et al.,
2012; Wang et al., 2013), CCI induced a clear expansion of Iba1-
positive cells in the injury-proximal tissue, with morphological
transformation from the typical ramified morphology to the
activation-associated ameboid phenotype (Loane and Byrnes, 2010)
(Fig. 4A). Importantly, salsalate treatment of injured animals signif-
icantly reduced the numbers of activated microglia/macrophages
Fig. 2. Transcriptomics analyses demonstrate that salsalate inhibits proinflammatory gene expression while increasing levels of transcripts encoding neuroprotection- or
neurogenesis-associated factors. (A, B) Transcriptome profiling analyses displayed as scatter plot of gene expression data normalized as fragments per kilobase of exon model
per million mapped (FPKM). Plots show (A) CCI-vehicle vs. naïve (no injury) and (B) CCI-vehicle vs. CCI-salsalate. In (A), dots above the diagonal represent genes more highly
expressed in the CCI-vehicle group, whereas dots below the diagonal are genes more highly expressed in naïve. In (B), dots above the diagonal represent genes more highly
expressed in the CCI-salsalate group, whereas dots below the diagonal are genes more highly expressed in CCI-vehicle. (C–E) Supervised hierarchical clustering analysis
heatmap showing expression of genes with statistically significant changes, as follows: (C) selected inflammatory response genes down-regulated by salsalate treatment; (D)
a set of 28 NF-jB-regulated genes that were down-regulated or up-regulated by salsalate treatment; and (E) selected neurogenesis- and neuroprotection-related genes
upregulated by salsalate treatment. Data were produced by RNA sequencing of injury site biopsies from 4 CCI-vehicle and 4 CCI-salsalate animals. Differential expression
analysis was performed using the Cufflinks & DE Analysis algorithm on the BaseSpace Onsite (Illumina, CA) with log2ratio > 1.0 and p-value < 0.05 filters. Gene set
enrichment was performed using Panther and GSEA on the GenePattern software platform (Broad Institute, MA).
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at the injury site, as quantified via anti-Iba1 intensity and numbers
of microglia/macrophages per section (Fig. 4A–C). Similarly,
astrocyte numbers at the injury site increased significantly in
response to CCI. Although we found reduced astrocyte expansion
in salsalate-treated animals, as measured by reduced GFAP stain-
ing intensity and reduced per section numbers of astrocytes
(Fig. 4D–F), these reductions were not statistically significant.
However, it is notable that in the salsalate treated group, astrocyte
numbers and GFAP fluorescence intensity were not statistically dif-
ferent from naïve controls, whereas astrocyte numbers and GFAP
fluorescence were significantly elevated in vehicle-treated CCI
animals in comparison to naive. Taken together, the data in Fig. 4
show that salsalate significantly diminishes TBI-dependent
activation and expansion of microglia/macrophages, with possible
attenuation of astrogliosis, as well. In combination with Figs. 2
and 3 data, these observations further confirm that salsalate
treatment reduces CCI-induced inflammation.
3.4. Treatment with salsalate alters the kinetics of infiltration and
persistence of myeloid cell populations
As the above histological analyses did not discriminate between
endogenous microglia and macrophages differentiated from CCI-
dependent infiltration of monocytes, we performed a flow cytom-
etry analysis to better define the myeloid populations in the
injured brain. Whole brains were processed at day +3 and day +7
relative to CCI to liberate leukocytes, and Percoll-fractionated cells
were stained with a panel of antibodies to define discrete myeloid
populations (see Materials and Methods for details). Total myeloid
cells were defined as the CD11b+ population, which represented
about 15% of the recovered cells and did not vary significantly
across groups (Fig. 5A). However, we did note a trend toward a
higher percentage of CD11b+ cells at day +3 in the CCI-salsalate
group and at day +7 in the CCI-vehicle group. Interestingly, these
trends became significant when the gated population was focused
on infiltrating myeloid cells, defined as CD11b+, CD45high. Specifi-
cally, the percentage of infiltrating myeloid cells was significantly
increased in the day +3 CCI-salsalate group, relative to both naïve
and CCI-vehicle. However, by day +7, this population was signifi-
cantly elevated only in the CCI-vehicle group relative to naïve,
whereas the infiltrating myeloid population in the CCI-salsalate
group did not significantly differ in comparison to either naïve or
CCI-vehicle. By contrast, there was no significant change in the per-
centage of microglia across treatments, with microglia gated either
as CD11b+, CD45low, or with more precise gating as CD11b+,
CD45low, Ly6Glow, Ly6Clow (Fig. 5A). Thus, the expansion of acti-
vated microglia/macrophages observed in the histological analyses
may represent a very local expansion not detectable at the level of
whole-brain microglia numbers, or it reflects a significant contri-
bution from blood-derived myeloid cells, which cannot be discrim-
inated from microglia based solely on morphology and Iba1
expression.
As the CD11b+, CD45high infiltrating myeloid cell population
represents a heterogeneous mix of myeloid cells, we also further
subdivided this population based on expression of the Ly6G and
Ly6C markers. Based on this analysis, we determined that neu-
trophils (CD11b+, CD45high, Ly6Ghigh, Ly6Clow) were significantly
elevated at Day +3 in the CCI-salsalate group, relative to both naïve
and CCI-vehicle (although this was a very rare population across all
samples) (Fig. 5A). Additionally, cells meeting an accepted defini-
tion of infiltrating inflammatory monocytes (CD11b+, CD45high,
Ly6Glow, Ly6Chigh) (Szulzewsky et al., 2015) were elevated at day
+3 in both the CCI-vehicle and CCI-salsalate groups, relative to
naïve. However, by day +7, this population was significantly
Fig. 3. Real-time PCR analysis of expression of mRNAs identified as differentially expressed by transcriptomics analyses. (A, B) TaqMan RT-PCR validation of (A) seven
inflammatory response genes identified as down-regulated by salsalate and (B) three neurogenesis- and neuroprotection-related genes upregulated by salsalate. Values are
fold-increase in expression comparing CCI-vehicle (Vehicle) to naïve, and CCI-salsalate (Salsalate) to naïve. *p < 0.05, Mann-Whitney U test, n = 8. (C) Pearson r analysis of
correlation between CCI-induced expression of the NF-jB-regulated inflammatory cytokine Tnf-a and three additional inflammatory cytokines (Ccl5, IL-1b, and Ccl2) and the
neuropeptide Oxy. n = 8 per group.
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Fig. 4. Salsalate reduces accumulation of activated microglia/macrophages at the site of TBI. (A) Immunofluorescence microscopy images of Iba1 expression in coronal
cryosections in a region proximal to the injury site at day +7 relative to CCI. (B,C) Quantification of Iba1 fluorescence intensity (B) and Iba1+ cells (C) in sections from (A).
****p < 0.0001, **p < 0.01, and *p < 0.05, one-way ANOVA with Tukey’s multiple comparisons test, n = 6 per group. (D) Immunofluorescence microscopy images of GFAP
expression in coronal cryosections in a region proximal to the injury site at day +7 relative to CCI. (E,F) Quantification of GFAP fluorescence intensity (E) and GFAP+ cells (F) in
sections from (D). ***p < 0.001 and *p < 0.05, one-way ANOVA with Tukey’s multiple comparisons test, n = 6 per group.
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elevated only in the CCI-vehicle group relative to naïve, with the
CCI-salsalate group not differing significantly from either naïve
or CCI-vehicle (Fig. 5A–B).
Overall, the above flow cytometry data show that salsalate
alters the kinetics of infiltration and persistence of blood derived
myeloid cells in the CCI-injured brain, with data suggesting a
salsalate-dependent acceleration in clearance of infiltrating mye-
loid populations by day +7, despite a larger presence of such cells
in salsalate-treated animals at day +3. Taken together with the data
in Fig. 4, these findings suggest that salsalate modifies the inflam-
matory response mediated by both injury-site resident microglia
and pro-inflammatory myeloid cells that infiltrate from the blood.
3.5. Salsalate treatment following TBI accelerates recovery of motor
function
Although the above data demonstrate a clear reduction in local
inflammation following TBI, such changes are only of potential
clinical relevance if they are correlated with functional recovery.
To quantify post-injury functional recovery, we employed two
assays of motor function, the rotarod and the beam cross. We have
previously shown that motor cortex-targeted CCI induces readily
quantifiable changes in motor ability, with progressive recovery
of function over the first week post-injury (Lagraoui et al., 2012).
To assess the impact of post-CCI salsalate treatment, we measured
Fig. 5. Salsalate alters the kinetics of infiltration and persistence of blood leukocytes following TBI. Brains were harvested from mice and leukocytes were purified by Percoll
gradient fractionation. (A) Quantification of the indicated leukocyte subsets in each treatment group (naïve, CCI-vehicle, CCI-salsalate) at day +3 and day +7 post-CCI,
expressed as a percentage of the total live-gated Percoll-purified leukocyte preparation. Markers used to define each subset are indicated for each population. Error bars are
SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05, two-way ANOVA with Tukey’s multiple comparisons test, n = 4 per group. (B) Primary flow cytometry data on day +7,
showing the expression of Ly6C and Ly6G in the CD11b+, CD45high (infiltrating myeloid cell) population. Treatment groups are indicated to the left and gates for neutrophils
and inflammatory monocytes are identified in the upper left plot. Numbers are quantification of inflammatory monocytes as a percentage of the total live-gated Percoll-
purified leukocyte preparation. Numbers are not shown for the neutrophil gate, as there was only a trace population which did not vary between groups.
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baseline performance at day 1 relative to CCI, and post-injury
performance at days +1, +3 and +7. As shown in Table 2, CCI caused
a significantly reduced latency to fall and reached speed at day 1
vs. day +1 in vehicle-treated animals, whereas there was no signif-
icant change in these parameters in salsalate-treated animals.
Additionally, although both groups showed significantly improved
performance in at least one of these parameters at day +3 vs. day
+1 and at day +7 vs. day +1, only the salsalate-treated group
demonstrated significant improvement in performance at day +7
vs. day 1. Furthermore, in the between groups comparison, the
rotarod performance in the salsalate-treated group was signifi-
cantly better than the vehicle-treated group at days +3 and +7
post-CCI (Fig. 6A–B). Moreover, whereas untreated animals did
not reach pre-injury performance levels until day +7, salsalate trea-
ted animals exceeded pre-injury performance by day +3 (with the
improvement being significant by day +7).
In the balance beam assay, the vehicle treated animals required
significantly more time to cross the beam on days +1 and +3 vs. day
1, whereas there was no significant difference in beam cross time
between day 1 and any other time point for salsalate-treated ani-
mals (Table 3). The vehicle-treated animals showed significant
recovery in performance between days +1 and +3 and days +1
and +7 (and the salsalate-treated animals did not demonstrate
recovery in function in this assay, because there was no significant
loss of function in this group). The between-groups comparison
reinforced these observations, demonstrating that the salsalate-
treated animals performed significantly better in the beam cross
time on days +1 and +3.
Analysis of beam cross foot slips data yielded similar findings,
with vehicle-treated animals exhibiting more foot-slips on days
+1, +3 and +7, relative to day1, whereas salsalate-treated animals
had significantly increased foot-slips only at day +1 vs. day 1.
Importantly, salsalate-treated animals exhibited significantly
reduced foot slips between day +1 and day +7, recovering to nearly
the pre-training performance level. By contrast, the vehicle-treated
animals did not exhibit a significant improvement following injury
(Table 3). In the between-groups comparison, salsalate-treated
animals had significantly fewer foot slips than the vehicle-
treated animals on days +3 and +7. Indeed, the untreated animals
remained severely impaired by this measure at day +7, making
approximately 3 as many foot slips as during the pre-injury mea-
surement (Fig. 6C–D). Finally, in the combined beam cross score,
the vehicle treated animals exhibited a significantly increased
overall score on days +1 and +3, relative to day 1, whereas there
was not a significant change in score for salsalate-treated animals
(although the value was very near significant for the salsalate-
treated animals on day +1 vs day 1, p = 0.0533) (Table 3). In the
beam cross score between-groups comparison, salsalate-treated
animals scored significantly better than vehicle-treated on day +3
(Fig. 6E). Taken together, these data show that salsalate treatment
results in both a significant acceleration of and improvement in
functional recovery in the 7 days following CCI injury.
4. Discussion
In this report, we have shown that salsalate treatment following
CCI reduced expression of a large number of NF-jB-regulated
inflammatory genes and promoted expression of a number of
genes which have known neuroprotective and neurogenic activi-
ties. Additionally, salsalate diminished accumulation of activated
microglia/macrophages (and possibly astrocytes) at the injury site,
and it altered the kinetics of accumulation of blood-derived mye-
loid cells, with an apparent reduction (vs. vehicle treatment) in
several distinct myeloid populations by day +7. The above tran-
scriptional and cellular changes correlated with improved recovery
of motor function, as assessed by two different behavioral assays.
Collectively, these data suggest that salsalate promotes a multifac-
torial biological response, promoting functional recovery from
penetrating TBI.
With respect to the repressed gene set, although reductions
were modest, they were consistently observed across numerous
inflammatory genes, suggesting a broad suppression of the inflam-
matory response. It is important to note that the inflammatory
response to CCI has a significant variability in magnitude, with a
high standard deviation. This high variability made the statistical
discrimination of modest effects on gene transcription more chal-
lenging in the real-time PCR assay. However, as the effects were
always repressive and always consistent with the RNA sequencing
data, there is a strong basis for our conclusion that salsalate
broadly inhibits the local inflammatory response to CCI. Moreover,
the CCI-induced inflammatory genes were highly correlated, sug-
gesting that the effect of salsalate was on a related gene set: specif-
ically the set of genes induced by NF-jB (Lagraoui et al., 2012).
Indeed, when comparing the CCI-vehicle group to the CCI-
salsalate group, 26 of 28 NF-jB-regulated genes with statistically
significant changes were downregulated by salsalate treatment.
Overall, these data are highly consistent with the known inhibitory
effect of salsalate/salicylate on the NF-jB pathway (Kopp and
Ghosh, 1994; Pierce et al., 1996; Yin et al., 1998).
In our examination of the effects of salsalate on inflammation-
associated glial responses, we observed a significantly reduced
expansion of activated microglia (and/or infiltrating monocytes/-
macrophages) at the site of CCI injury, with a possible reduction
in numbers of activated astrocytes. Additionally, our flow cytome-
try analysis of leukocyte populations revealed salsalate-dependent
changes in the kinetics of recruitment and/or persistence of speci-
fic blood leukocyte populations. At the day +3 and day +7 time
points, neutrophils were detected at very low levels, but with sig-
nificantly increased numbers in the day +3 CCI-salsalate group, rel-
ative to both naïve and CCI-vehicle. Studies of blood leukocyte
recruitment in TBI have shown that neutrophils are primarily
located in meninges proximal to the site of injury, and tend to be
found in the parenchyma only at the focal site of injury, if at all
(Corps et al., 2015; Soares et al., 1995). As our tissue preps for flow
cytometry did not include the meninges, the low representation of
Table 2
Within-group statistics for rotarod assay.
Rotarod latency to fall
CCI + vehicle CCI + salsalate
Comparison Significance Comparison Significance
D1 vs. D+1 *** D1 vs. D+1 ns
D1 vs. D+3 ns D1 vs. D+3 ns
D1 vs. D+7 ns D1 vs. D+7 **
D+1 vs. D+3 * D+1 vs. D+3 ***
D+1 vs. D+7 ⁄⁄⁄⁄ D+1 vs. D+7 ⁄⁄⁄⁄
D+3 vs. D+7 ns D+3 vs. D+7 ns
Rotarod reached speed
CCI + vehicle CCI + salsalate
Comparison Significance Comparison Significance
D1 vs. D+1 *** D1 vs. D+1 ns
D1 vs. D+3 ns D1 vs. D+3 ns
D1 vs. D+7 ns D1 vs. D+7 **
D+1 vs. D+3 ns D+1 vs. D+3 ***
D+1 vs. D+7 ⁄⁄⁄⁄ D+1 vs. D+7 ⁄⁄⁄⁄
D+3 vs. D+7 * D+3 vs. D+7 ns
**** p < 0.0001.
*** p < 0.001.
** p < 0.01 and.
* p < 0.05.
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neutrophils is not surprising. The significant elevation of neu-
trophils in the CCI-salsalate group at day +3 may represent
enhanced accumulation of this cell type at the injury site, and it
may thus be biologically significant, despite the low percentages
relative to other subsets. As data suggest that neutrophils can be
both neuroprotective and pathologic in the context of TBI (Corps
et al., 2015), the impact of enhanced neutrophil presence at day
+3 following salsalate treatment will require further investigation.
We also observed a change in the kinetics of persistence of infil-
trating myeloid cells in the CCI-salsalate group. Both the broadly
defined population of CD11b+, Cd45high blood-derivedmyeloid cells
and the more strictly defined CD11b+, CD45high, Ly6Glow, Ly6Chigh
infiltrating inflammatory monocytes were significantly elevated
(vs. naive) at day +3 in the CCI-vehicle and CCI-salsalate groups.
However, by day +7, only the CCI-vehicle group had significant ele-
vations of these populations vs. naive. These data suggest a more
rapid resolution of the inflammatory response in salsalate-treated
animals. Moreover, in comparing the CCI-salsalate group to CCI-
vehicle in our RNA sequencing data and flow cytometry analyses,
we observed reduced transcription of inflammatory genes at day
+3, despite the significantly increased percentages of infiltrating
myeloid cells and neutrophils in the CCI-salsalate group and similar
percentages of inflammatory monocytes in both groups. These data
suggest that the anti-inflammatory effects of salsalate at day +3 are
the result of suppression of inflammatory gene expression without
inhibition of recruitment of blood leukocytes. However, by day +7,
the recruitment and/or retention of blood leukocytes is diminished
by salsalate, presumably as a consequence of repression of inflam-
matory cytokines, many of which are chemokines.
Although the analysis of microglia by flow cytometry did not
reveal significant changes in this cell type at either time point, this
is not surprising, as the CCI injury is focal, impacting microglia
populations only in the injury-proximal region of the brain par-
enchyma. Thus, changes in resident microglia numbers were
detectable by histological examination of the local injury site, but
not by flow cytometry analysis of the leukocyte content of the
entire brain.
Overall, our data show that salsalate suppresses the injury-
induced inflammatory response at both the gene expression and
cellular levels. Importantly, salsalate mediates the above anti-
inflammatory effects without inhibition of the clotting cascade
(Sweeney and Hoernig, 1991). In contrast to aspirin and most
Fig. 6. Post-TBI salsalate treatment results in improved recovery of motor function following TBI. (A, B) Assessment of (A) latency to fall and (B) maximum speed attained on
an accelerating rotarod. (C, D, E) Assessment of (C) crossing time latency, (D) number of foot slips and (E) overall score on a balance beam test (see Materials and Methods).
***p < 0.001, **p < 0.01 and *p < 0.05, two-way analysis of variance (ANOVA) with Sidak’s multiple comparisons test, n = 9 per group.
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NSAIDs, which are potent Cox-1 inhibitors, salsalate has a very
high IC50 for both Cox-1 and Cox-2 (4956 lM and 482 lM, respec-
tively) (Marnett, 2009). Clearly, the absence of an anticoagulant
effect in the context of brain injury is highly desirable, as even
minor brain hemorrhage can have catastrophic consequences.
The magnitude of the in vivo reduction of the injury-induced
pro-inflammatory program was smaller in comparison to what
we observed in our in vitro analyses of microglia responses to
LPS stimulation. One key difference between these experiments
is that in vitro studies were performed as pre-treatments whereas
salsalate administration in vivo was performed 30 min post-injury.
Thus, the inflammatory cascade was blocked from the outset in
BV2 cells, whereas there was a significant period of initiation of
inflammation prior to salsalate exposure in vivo. We also surmise
that the concentration of salsalate in the brain may not reach the
concentration required for highly effective suppression of inflam-
mation, and/or that the once-per-day administration of this drug
results in periods of diminished salicylate concentration in the
brain, relaxing the block on NF-jB activation. Significant fluctua-
tions in plasma salicylate concentration do occur in rodents and
man over a 16-h period following salsalate ingestion (Cao et al.,
2012; Harrison et al., 1981), suggesting that more frequent dosing
would be required to maintain a consistent concentration in blood
plasma and the CNS parenchyma.
While it is tempting to speculate that better suppression of the
inflammatory response would further improve functional out-
comes, this may not be the case. Indeed, the inflammatory and
post-injury healing response consists of many elements that inhi-
bit CNS neuroregeneration (Silver et al., 2015), including the glial
scar (Bush et al., 1999; Cafferty et al., 2007; Ridet et al., 1997).
However, the inflammatory response is also required for healing
of brain injuries; therefore, a complete block of the inflammatory
response would be detrimental (Ziebell and Morganti-Kossmann,
2010). Thus, the ideal TBI therapy would preserve the healing
aspects of the inflammatory response, while interfering with those
activities that inhibit repair and replacement of damaged and dead
neurons (Kumar and Loane, 2012). It is intriguing to speculate that
the modest inhibition of inflammation by salsalate observed in this
study may actually be of more therapeutic benefit than alternative
treatments that achieve a stronger blockade of this response. Fur-
ther comparative studies would be required to definitively address
this hypothesis.
Although salsalate/salicylate has been known as an NF-jB inhi-
bitor for more than 20 years, recent work has also identified IKK/
NF-jB-independent effects, including activation of adenosine
monophosphate-activated protein kinase (AMPK) (Hawley et al.,
2012) and inhibition of CBP and p300 lysine acetyltransferase
activity (Shirakawa et al., 2016). Moreover, salicylate stimulation
of p300 has recently been shown to prevent tau acetylation on
lysine 174 and lower total levels of tau in a mouse model of Alzhei-
mer’s disease, resulting in functional improvement (Min et al.,
2015). As data suggest that tau also has a pathological role in
TBI-induced neurodegeneration, particularly in the context of
repeated TBI and chronic traumatic encephalophathy (CTE)
(Daneshvar et al., 2015; Ojo et al., 2016; Washington et al.,
2016), the p300-tau pathway represents another NF-jB-
independent target of salsalate, which may further augment func-
tional recovery from TBI. Additionally, salsalate therapy would also
suppress the inflammatory response of peripheral immune system,
which may lead to therapeutic benefit in TBI associated with poly-
trauma, which is common in military TBI and motor vehicle acci-
dents. In this regard, there is increasing evidence of a variety of
mechanisms by which peripheral immune responses impact CNS
function (Marin and Kipnis, 2016). Further investigation will be
required to determine if any of the above activities of salsalate con-
tribute to the therapeutic benefit for TBI, reported in this work.
Interestingly, salsalate is currently being explored as a therapy
for diabetes and pre-diabetes (Goldfine et al., 2008; Knudsen and
Pedersen, 2015). While considerable data suggest that the IKKb-
suppressing anti-inflammatory activity of salsalate is responsible
for the therapeutic benefit (Knudsen and Pedersen, 2015; Yuan
et al., 2001), this interpretation may be too simplistic, as there
are indications that salsalate-mediated AMPK activation is also
critical for efficacy in treatment of diabetes (Steinberg et al.,
2013). Thus, the success of salsalate as a diabetes therapy may
be due to the unique spectrum of diverse biological processes
altered by this drug.
In this work, we found that salsalate promotes transcription of
numerous genes that are associated with neuroprotection and/or
neurogenesis. Among this group of genes were Eomes (also known
as Tbr2), a transcription factor required for adult neurogenesis in
the dentate gyrus (Hodge et al., 2012); Lhx8, a transcription factor
that drives production of interneuron progenitors (Flandin et al.,
2011); Dlx5, a transcription factor involved in neurogenesis and
positioning of the developing neural crest (McLarren et al., 2003;
Perera et al., 2004); Dcx, a key regulator of neuronal migration
(Wynshaw-Boris et al., 2010); and Meis2 and Six3, two homeobox
transcription factors involved in neurogenesis (Agoston et al.,
2014; Appolloni et al., 2008). Additional upregulated genes
included the regulators of neuronal development, Frdm7, and the
retinoic acid receptor, Rarb (Betts-Henderson et al., 2010; Rataj-
Baniowska et al., 2015; Serpente et al., 2005). Other salsalate-
induced genes include the dopamine receptors, Drd1a and Drd2,
which have been shown to mediate neuroprotection in the context
of neurodegenerative pathologies such as Parkinson’s disease
(Calabresi et al., 2013; Lewis et al., 2006). Although our real-time
PCR analysis in Fig 2F failed to show statistically significant eleva-
tion of two selected genes from this set (Eomes and Lhx8), the high
representation of neurogenesis/neuroprotection-associated factors
Table 3
Within-group statistics for beam cross assay.
Beam cross time
CCI + vehicle CCI + salsalate
Comparison Significance Comparison Significance
D1 vs. D+1 ⁄⁄⁄⁄ D1 vs. D+1 ns
D1 vs. D+3 ** D1 vs. D+3 ns
D1 vs. D+7 ns D1 vs. D+7 ns
D+1 vs. D+3 ** D+1 vs. D+3 ns
D+1 vs. D+7 ⁄⁄⁄⁄ D+1 vs. D+7 ns
D+3 vs. D+7 ns D+3 vs. D+7 ns
Beam cross foot slips
CCI + vehicle CCI + salsalate
Comparison Significance Comparison Significance
D1 vs. D+1 * D1 vs. D+1 **
D1 vs. D+3 ⁄⁄⁄⁄ D1 vs. D+3 ns
D1 vs. D+7 * D1 vs. D+7 ns
D+1 vs. D+3 ns D+1 vs. D+3 ns
D+1 vs. D+7 ns D+1 vs. D+7 **
D+3 vs. D+7 ns D+3 vs. D+7 ns
Beam cross score
CCI + vehicle CCI + salsalate
Comparison Significance Comparison Significance
D1 vs. D+1 ** D1 vs. D+1 ns
D1 vs. D+3 ** D1 vs. D+3 ns
D1 vs. D+7 ns D1 vs. D+7 ns
D+1 vs. D+3 ns D+1 vs. D+3 ns
D+1 vs. D+7 ns D+1 vs. D+7 ns
D+3 vs. D+7 ns D+3 vs. D+7 ns
**** p < 0.0001.
** p < 0.01.
* p < 0.05.
M. Lagraoui et al. / Brain, Behavior, and Immunity 61 (2017) 96–109 107
in a relatively small gene set (13/81 genes induced by salsalate)
suggests that these elevations may be biologically significant.
Among the genes identified as induced by salsalate treatment in
our transcriptomics analyses, the neuropeptides Oxy and Trh are
particularly intriguing as potential contributors to functional
recovery. Oxytocin has been shown to mediate both the ‘‘social
neuroprotection” effect following stroke and to repress microglia
activation in vitro (Karelina et al., 2011). Other recent reports con-
nect oxytocin to peripheral neuroregeneration and wound healing
(Gumus et al., 2015; Poutahidis et al., 2013), suggesting possible
benefits to healing in the context of CCI injury. Analogs of Trh have
been extensively studied in TBI, with benefits shown in many
experimental models. Moreover, these Trh mimetics promote
diverse activities, including protection from apoptosis, reduction
of microglia activation, and increased production of neurotrophic
and neuroprotective molecules (Loane et al., 2015). Although con-
trol of oxytocin gene expression remains incompletely understood,
one of the most studied regulatory elements consist of a variety of
hormone receptor binding sites (Burbach et al., 2001; Gainer,
2012). Regulation by NF-jB (either positive or negative) has not
been reported, to our knowledge. However, data suggest that the
oxytocin promoter is responsive to RARb (Burbach et al., 2001),
one of the transcripts upregulated by salsalate, perhaps suggesting
a mechanism whereby salsalate stimulates increased production of
the oxytocin mRNA. Interestingly, NF-jB has been reported as a
repressor of Trh in the context of LPS injection (de Vries et al.,
2016). The induction of Trh may therefore reflect release of NF-
jB-mediated suppression by salsalate treatment. Thus, the
observed induction of neuroprotective and neurogenesis-
associated genes likely reflects effects of salsalate that are both
dependent and independent of inhibition of NF-jB.
We also observed upregulation of another neuropeptide, vaso-
pressin (Avp), which is closely linked to Oxy and believed to have
arisen by a gene duplication event. Both neuropeptides are
expressed by the hypothalamo-neurohypophysial system
(Burbach et al., 2001). However, unlike oxytocin, existing data sug-
gest that induction of vasopressin in the context of TBI is detrimen-
tal through mechanisms that include disruption of the blood-brain
barrier and promotion of cerebral edema (Trabold et al., 2008).
However, one study suggests that these negative effects are pri-
marily due to amplification of the inflammatory pathway
(Szmydynger-Chodobska et al., 2010). Therefore, as salsalate inhi-
bits inflammation, we expect that vasopressin-mediated induction
of inflammatory genes may be ameliorated, thereby negating detri-
mental effects of upregulation of the Avp gene.
Given the uniform lack of success of clinical trials of TBI thera-
peutics to date (Maas et al., 2012, 2010), many in the TBI field now
argue that multifactorial therapies are required, either in the form
of multiple drugs targeting distinct aspects of the pathological
response, or single drugs with multiple effects (Loane et al.,
2015; Margulies et al., 2009; Stoica et al., 2009; Vink and
Nimmo, 2009). However, this strategy has also not yet met with
success, as evidenced by failure of a recent clinical trial with pro-
gesterone therapy for severe TBI (Skolnick et al., 2014). Thus, it
remains unclear which combination of biological activities are
required for successful treatment of human TBI. In this regard, sal-
salate may be a promising candidate for further investigation as a
TBI therapy, given diverse effects on suppressing inflammation,
promoting transcription of neuroprotective and neurogenic genes,
and diminishing acetylation and accumulation of tau.
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